Biosimilar cell lines
Ready to go, high expressing manufacturing biosimilar cell lines ready for development
Polpharma Biologics has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.
Cell line available
GMP-ready, stable, high producing cell lines
These biosimilar cell lines are generated on our proprietary CHO-based platform, CHO ® using (animal component free) of the shelf culture medium.
| Biosimilar to | Antibody |
|---|---|
| Herceptin® | Trastuzumab |
| Humira® | Adalimumab |
| Erbitux® | Cetuximab |
| Avastin® | Bevacizumab |
| Rituxan/MabThera® | Rituximab |
| Enbrel® | Etanercept |
| Synagis® | Palivizumab |
| Xolair® | Omalizumab |
| Yervoy® | Ipilimumab |
| Perjeta® | Pertuzumab |
| Opdivo® | Nivolumab |
| Keytruda® | Pembrolizumab |
Outlicesing and partnerships available
Biosimilar programs are ready for tech transfer to a CMO of your choice or you can use our own CDMO services to advance to the clinic rapidly. Our cell lines and programs in different development stages, can be found in the table below. If a biosimilar that you are interested in is not listed contact us as we may have it in late stage development or can develop a cell line for you.